Cancer Vaccines Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Funding
• Clinical Trials
• Forums

IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer
Conditions:   High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma;   Stage 0a Bladder Cancer AJCC v8;   Stage 0is Bladder Cancer AJCC v8;   Stage I Bladder Cancer AJCC v8 Interventions:   Biological: PD-L1/IDO Peptide Vaccine;   Biological: Pembrolizumab Sponsors:   Mamta Parikh;   IO Biotech;   National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 6, 2023 Category: Research Source Type: clinical trials

A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)
Conditions:   Leptomeningeal Disease;   Triple Negative Breast Cancer;   HER2-positive Breast Cancer Intervention:   Biological: Dendritic Cell Vaccine Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   United States Department of Defense Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2023 Category: Research Source Type: clinical trials